Elite Pharmaceuticals Reports Q4 2026 Results: Full Earnings Call Transcript

Elite Pharmaceuticals (OTC: ELTP ) released fourth-quarter financial results and hosted an earnings call on Tuesday.

Read the complete transcript below.

This content is powered APIs.

For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Elite Pharmaceuticals Inc reported a substantial 77% increase in total revenues for fiscal year 2026, reaching $149 million, marking another year of record revenue growth.

Operating income rose by 151% to $49 million, attributed to a successful product line expansion and improved product mix yielding better margins.

The company reported a significant improvement in cash flow, with operating cash flow increasing by 219% to $23.7 million and a strengthening balance sheet, highlighted by a 163% increase in cash and a reduction in long-term debt by 20%.

Elite Pharmaceuticals launched several new generic products over the past year, including methadone and filed for a generic coagulant, emphasizing their commitment to pipeline development and sustained growth.

Management highlighted the company's strong market position, successful internal product development strategy, and readiness for potential NASDAQ listing, underscoring a positive outlook for continued growth and investment attractiveness.

Full Transcript OPERATOR Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Year End of Fiscal Year 2026 conference call.

At this time, all lines are placed on a listen-only mode.

Before management begins speaking, the conference has the following: Elite Pharmaceuticals Inc would like to remind listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time, including, but not limited to, statements about Elite's expectations regarding forward operating results.

Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations.

Actual results may differ materially.

Elite disclaims any obligation to update or revise its forward-looking statements except as required by law.

More complete information regarding forward-looking statements, risks, and uncertainties can be found in the reports Elite files with the SEC, which are available on Elite's website at ElitePharma.com under the Investor Relations section.

Elite encourages you to review these documents carefully.

With that covered, it is now my pleasure to turn the floor over to your host, Mr.

Nasrat Hakim, President and Chief Executive Officer of Elite Pharmaceuticals.

Sir, the floor is yours.

Nasrat Hakim, President & CEO Thank you, Matthew.

And good morning, ladies and gentlemen, and thank you for joining us today.

My name is Nasrat Hakim.

I am Elite's Chairman and CEO.

This is our earnings call.

Our CFO, Carter Ward, will give us the financial update, after which I'll come back with a brief update and answer some of the questions you've submitted to Diane.

Mr.

Ward, you have the floor.

Carter Ward Thank you, Nasrat.

And good morning, everybody.

Yesterday we filed our 10-K, which is our annual report for the fiscal year ended March 31, 2026.

We're in a March fiscal year 10-K.

If you haven't seen it yet, it's available at our website, ElitePharma.com, under the Investor Relations section.

Today, as usual, we're going to provide some context and some color to the financial statements and also answer the finance questions I received overnight and questions we got over the weekend even.

And as always, thank you so much for those questions.

We really appreciate you taking the time to ask them.

Let me start with the P&L first.